Company NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris 19:55:00 05/10/2026 +04			5-day change	1st Jan Change
0.6500 ^EUR	-2.84%		-10.71%	-44.82%

07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

Business description: NFL Biosciences

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.

At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Number of employees: 4

Sales by Activity: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Biotechnology (Startups)	39	22	200K	46	188

See all business segments

Geographical breakdown of sales: NFL Biosciences

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
France	39	22	200K	46	188

See all geographic segments

Executive Committee: NFL Biosciences

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	17/10/2024
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-
Ignacio Faus CEO	Chief Executive Officer	-	19/05/2021
Lara Babich PRN	Corporate Officer/Principal	-	01/01/2024

See NFL BIOSCIENCES governance

Composition of the Board of Directors: NFL Biosciences

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	27/02/2023
Bruno Lafont CHM	Chairman	-	17/10/2024
Francis Ahner BRD	Director/Board Member	-	19/05/2021
Yannick Plétan BRD	Director/Board Member	-	19/05/2021
Dominique Côté BRD	Director/Board Member	-	01/06/2023

Composition of the Board of Directors

Shareholders: NFL Biosciences

Name	Stocks	%	Valuation
Friedland Gestion SAS 0.1609 %	20,395	0.1609 %	21 322 €

List of NFL BIOSCIENCES shareholders

Company details: NFL Biosciences

NFL Biosciences SAS

199 rue Hélène Boucher

34170, Castelnau-le-Lez

+33 4 11 93 76 67

http://www.nflbiosciences.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-2.84%	-10.71%	-49.85%	-55.23%	9.54M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.81%	+19.51%	+78.12%	57.39B
LONZA GROUP AG	+1.63%	-1.61%	+3.16%	+36.89%	47.64B
REVOLUTION MEDICINES, INC.	+0.64%	+3.33%	+347.53%	+725.26%	44.29B
IQVIA HOLDINGS INC.	+2.26%	-2.69%	+28.62%	+33.30%	42.5B
BEONE MEDICINES AG	+0.93%	-1.79%	+4.62%	+111.19%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+1.26%	-1.36%	-7.07%	-11.03%	24.34B
Average	+0.82%	-1.56%	+43.65%	+109.36%	39.05B
Weighted average by Cap.	+1.45%	-0.84%	+58.22%	+136.89%